Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Histological or cytological diagnosis of non-squamous, non-small cell lung cancer. Mixed tumors will be categorized by the predominant cell type unless small cell elements are present, in which case the patient is ineligible.~* Stage wet IIIB-IV or recurrent disease~* No significant hemoptysis (bright red blood\< 1/2 teaspoon or more per episode within 3 months)~* Performance status of 0-1~* Prior radiation allowed if \> 15 days.~* No prior treatment for metastatic disease. Adjuvant treatment allowed if greater than 6 months has passed.~Exclusion Criteria~Disease-Specific Exclusions~* History of hemoptysis (bright red blood of 1/2 teaspoon or more per episode) within 3 months prior to study enrollment.~* Current, ongoing treatment with full-dose warfarin~* Current or recent (within 10 days of enrollment) use of aspirin (\>325 mg/day) or chronic use of other NSAIDs.~* Performance status =2-4~* Known HIV-related disease~General Medical Exclusions~Subjects meeting any of the following criteria are ineligible for study entry:~* Inability to comply with study and/or follow-up procedures~* Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study~Bevacizumab (Avastin®)-Specific Exclusions~* Inadequately controlled hypertension (defined as systolic blood pressure \>150 and/or diastolic blood pressure \> 100 mmHg on antihypertensive medications)~* Any prior history of hypertensive crisis or hypertensive encephalopathy~* New York Heart Association (NYHA) Grade II or greater congestive heart failure (see Appendix E)~* History of myocardial infarction or unstable angina within 6 months prior to study enrollment~* History of stroke or transient ischemic attack within 6 months prior to study enrollment~* Significant vascular disease (e.g., aortic aneurysm, aortic dissection)~* Symptomatic peripheral vascular disease~* Evidence of bleeding diathesis or coagulopathy~* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study~* Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment~* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment~* Serious, non-healing wound, ulcer, or bone fracture~* Proteinuria at screening as demonstrated by either~* Urine protein:creatinine (UPC) ratio \> 1.0 at screening OR~* Urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible).~* Known hypersensitivity to any component of bevacizumab~* Pregnant (positive pregnancy test) or lactating. Use of effective means of contraception (men and women) in subjects of child-bearing potential

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete